You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Late-Breaking Data on LDL-C Reduction: siRNA and PCSK9 in the Spotlight

  • Authors: Marc S. Sabatine, MD, MPH; Kausik K. Ray, MD, MPhil, FRCP
  • CME / ABIM MOC Released: 9/25/2019
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 9/25/2020, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists (lipidologists), primary care providers, and endocrinologists.

The goal of this activity is to review new strategies to reduce low-density lipoprotein cholesterol (LDL-C) in patients with high-risk atherosclerotic cardiovascular disease (ASCVD), including an emerging mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) small interfering RNA (siRNA) and recent clinical trial data associated with this approach.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of action of new agents used to lower LDL-C in high-risk patients with ASCVD
    • Latest clinical data on the use of siRNA PCSK9 in patients with high-risk ASCVD
    • New strategies to lower LDL-C in high-risk patients with ASCVD 


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Marc S. Sabatine, MD, MPH

    Professor of Medicine
    Harvard Medical School
    Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine
    Chairman, TIMI Study Group
    Boston, Massachusetts, United States

    Disclosures

    Disclosure: Marc S. Sabatine, MD, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; Anthos Therapeutics; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; CVS Caremark; DalCor; IFM Therapeutics; Intarcia Therapeutics, Inc.; The Medicines Company; MedImmune Inc.; Merck & Co., Inc.
    Received grants for clinical research from: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Daiichi Sankyo, Inc.; Eisai Inc.; Intarcia Therapeutics, Inc.; The Medicines Company; MedImmune Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Quark Pharmaceuticals

  • Kausik K. Ray, MD, MPhil, FRCP

    Professor of Public Health
    Imperial College London
    London, United Kingdom

    Disclosures

    Disclosure: Kausik Ray, MD, MPhil, FRCP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; AKCEA; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Cerenis; Daiichi Sankyo, Inc.; Esperion Therapeutics, Inc.; Ionis; Kowa Company Ltd.; Lilly; Medco; Novo Nordisk A/S; Regeneron Pharmaceuticals, Inc.; Sanofi; Silence Therapeutics
    Served as a speaker or a member of a speakers bureau for: Algorithm; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; CIPLA; Dr. Beddy's; Kowa Company Ltd.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.; Zuelling Pharma
    Received grants for clinical research from: Amgen Inc.; MSD; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi

Editor

  • George Boutsalis, PhD

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as advisor or consultant for: ViiV Healthcare
    Owns stocks, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Late-Breaking Data on LDL-C Reduction: siRNA and PCSK9 in the Spotlight

Authors: Marc S. Sabatine, MD, MPH; Kausik K. Ray, MD, MPhil, FRCPFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 9/25/2019

Valid for credit through: 9/25/2020, 11:59 PM EST

processing....

 

  • Print